{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:36:52Z","timestamp":1784353012013,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.diagmicrobio.2020.115007","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T02:36:34Z","timestamp":1580265394000},"page":"115007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017\u20132018"],"prefix":"10.1016","volume":"97","author":[{"given":"Shawn A.","family":"Messer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0005","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10096-015-2374-1","article-title":"Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification","volume":"34","author":"Araujo","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0020","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/j.1875-9114.2012.01124","article-title":"Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options","volume":"32","author":"Ashley","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0025","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.03.023","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","volume":"23","author":"Astvad","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/cid\/ciz156","article-title":"Invasive fungal infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis","volume":"70","author":"Baker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0035","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0040","article-title":"Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates","volume":"4","author":"Buil","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijantimicag.2014.06.007","article-title":"Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections","volume":"44","author":"Castanheira","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0050","series-title":"Manual of clinical microbiology","first-page":"2030","article-title":"Aspergillus and Penicillium","author":"Chen","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0055","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant aspergillosis: epidemiology, molecular mechanisms","volume":"216","author":"Chowdhary","year":"2017","journal-title":"and treatment J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0060","series-title":"M38Ed3. Reference method for broth dilution antifungal susceptibilty testing of filamentous fungi","author":"CLSI","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0065","series-title":"M59Ed2. Epidemiological cut-off values for antifungal susceptibility testing","author":"CLSI","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0070","series-title":"M61Ed1. Performance standards for antifungal susceptibility testing of filamentous fungi","author":"CLSI","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0080","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cut-off values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0085","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cut-off values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0090","article-title":"Posaconazole MIC distributions for Aspergillus fumigatus SC by four methods: impact of Cyp51A mutations on estimation of epidemiological cut-off values (ECVs\/ECOFFs)","volume":"64","author":"Espinel-Ingroff","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0095","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/myc.12912","article-title":"Systemic antifungal drug use in Belgium\u2014one of the biggest antifungal consumers in Europe","volume":"62","author":"Goemaere","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0100","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/cid\/cix297","article-title":"Changes in in vitro susceptibility patterns of aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999-2015","volume":"65","author":"Heo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0115","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.04223-14","article-title":"Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0120","series-title":"February 21\u201325","first-page":"552","article-title":"Comparison of therapeutic drug levels of adult and pediatric patients undergoing treatment for fungal diseases. BMT Tandem Meetings","volume":"2018","author":"Kleiboeker","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/jof1030345","article-title":"Role of new antifungal agents in the treatment of invasive fungal infections in transplant recipients: Isavuconazole and new posaconazole formulations","volume":"1","author":"Li","year":"2015","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0135","doi-asserted-by":"crossref","first-page":"s140","DOI":"10.1093\/ofid\/ofy210.366","article-title":"Invasive pulmonary aspergillosis (IPA) complicating respiratory viral infections in patients with hematological malignancies","volume":"5","author":"Magira","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0140","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0145","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1111\/j.1439-0507.2011.02032.x","article-title":"Emerging moulds: epidemiological trends and antifungal resistance","volume":"54","author":"Miceli","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy","volume":"9","author":"Natesan","year":"2016","journal-title":"and clinical recommendations. Infect Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2146\/ajhp100423","article-title":"Antifungal use in hospitalized adults in U.S. academic health centers","volume":"68","author":"Pakyz","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1060028015581679","article-title":"Isavuconazole: a new option for the management of invasive fungal infections","volume":"49","author":"Pettit","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0165","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/JCM.42.10.4419-4431.2004","article-title":"Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus","volume":"42","author":"Pfaller","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0170","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/JCM.02136-10","article-title":"Use of epidemiological cut-off values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-012-9551-x","article-title":"Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program","volume":"174","author":"Pfaller","year":"2012","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01230-18","article-title":"In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0190","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3201\/eid2009.140142","article-title":"Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011\u20132013","volume":"20","author":"Pham","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0195","doi-asserted-by":"crossref","unstructured":"Rivero-Menendez, O., Alastruey-Izquierdo, A., Mellado, E., & Cuenca-Estrella, M. (2016) Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi (Basel), 2: E21.","DOI":"10.3390\/jof2030021"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12879-018-3410-4","article-title":"Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America","volume":"18","author":"Stultz","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0210","doi-asserted-by":"crossref","unstructured":"Toda, M., Beer, K., O'Halloran, A., Reingold, A., Alden, N., Yousey-Hindes, K., Anderson, E.J., Bohm, S., McMahon, M., Butler, L., Pradhan, E., Felsen, C.B., L., B., Thomas, A., Talbot, K., Reed, G.M., Chiller, T., Garg, S., & Jackson, B.R. (2018) Evidence of aspergillosis among patients with influenza-associated hospitalizations \u2014 United States, 2005\u20132017. Open Forum Infect Dis, 5: S139-S140.","DOI":"10.1093\/ofid\/ofy210.365"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0215","series-title":"4: ofw268","article-title":"Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000\u20132013. Open Forum Infect Dis","author":"Vallabhaneni","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0220","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/jac\/dky270","article-title":"Trends in antifungal use in US hospitals, 2006\u201312","volume":"73","author":"Vallabhaneni","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0225","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dku364","article-title":"Azole, polyene and echinocandin MIC distributions for wild-type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands","volume":"70","author":"van Ingen","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0235","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/JCM.02478-15","article-title":"First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States","volume":"54","author":"Wiederhold","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0250","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/TCRM.S90335","article-title":"Role of isavuconazole in the treatment of invasive fungal infections","volume":"12","author":"Wilson","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0255","series-title":"Manual of clinical microbiology","first-page":"2057","article-title":"Fusarium and other opportunitistic hyaline fungi","author":"Zhang","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2020.115007_bb0260","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciy181","article-title":"Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009\u20132013","volume":"67","author":"Zilberberg","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319312301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319312301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:50Z","timestamp":1760003570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319312301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0732889319312301"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115007","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017\u20132018","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115007"}}